AbbVie (NYSE:ABBV) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of AbbVie (NYSE:ABBV) from a buy rating to a strong-buy rating in a research report sent to investors on Saturday morning.

A number of other equities analysts have also recently commented on ABBV. Bank of America lifted their price objective on shares of AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. Hsbc Global Res raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, December 10th. UBS Group lifted their price target on shares of AbbVie from $195.00 to $220.00 and gave the stock a “neutral” rating in a research note on Friday, November 7th. Erste Group Bank downgraded shares of AbbVie from a “buy” rating to a “hold” rating in a research note on Tuesday, October 14th. Finally, Guggenheim increased their target price on AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a research note on Monday, October 20th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $244.55.

AbbVie Stock Up 1.9%

ABBV opened at $227.53 on Friday. AbbVie has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.60 and a current ratio of 0.72. The stock has a market cap of $402.14 billion, a price-to-earnings ratio of 172.37, a price-to-earnings-growth ratio of 1.21 and a beta of 0.36. The firm’s fifty day moving average is $227.20 and its 200 day moving average is $210.24.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The company had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The firm’s revenue was up 9.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, sell-side analysts forecast that AbbVie will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a $1.73 dividend. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a yield of 3.0%. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s dividend payout ratio is presently 496.97%.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Marshall & Sullivan Inc. WA acquired a new position in shares of AbbVie in the 2nd quarter valued at $25,000. Evolution Wealth Management Inc. purchased a new position in AbbVie during the 2nd quarter worth approximately $26,000. Chelsea Counsel Co. purchased a new stake in shares of AbbVie in the 3rd quarter valued at $26,000. TD Capital Management LLC increased its stake in shares of AbbVie by 82.9% in the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after acquiring an additional 58 shares during the period. Finally, Spurstone Advisory Services LLC acquired a new position in AbbVie during the second quarter valued at $28,000. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.